Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3 EUR | +1.35% | 0.00% | -18.45% |
Mar. 27 | Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment | MT |
Mar. 25 | Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024 |
Sales 2024 * | 11.5M 12.26M | Sales 2025 * | 15M 15.99M | Capitalization | 138M 147M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 12 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.2 x |
P/E ratio 2024 * |
-9.87
x | P/E ratio 2025 * |
-22.8
x | Employees | 95 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 16.94% |
Latest transcript on Heidelberg Pharma AG
1 day | +1.35% | ||
Current month | -2.24% | ||
1 month | +1.67% | ||
3 months | -7.85% | ||
6 months | -3.17% | ||
Current year | -18.45% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Pahl
CEO | Chief Executive Officer | - | 11-12-31 |
Walter Miller
DFI | Director of Finance/CFO | - | 23-04-30 |
András Strassz
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 05-04-28 | |
Georg F. Baur
BRD | Director/Board Member | 74 | 00-12-13 |
Birgit Kudlek
BRD | Director/Board Member | 57 | 12-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 3.05 | +3.04% | 300 |
24-04-18 | 2.96 | 0.00% | 4,406 |
24-04-17 | 2.96 | -2.31% | 27,716 |
24-04-16 | 3.03 | -0.66% | 6,387 |
24-04-15 | 3.05 | 0.00% | 84 |
Delayed Quote Xetra, April 19, 2024 at 03:02 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.45% | 147M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.43% | 21.66B | |
-18.35% | 20.77B | |
-8.75% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- HPHA Stock